<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39396980</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Impact of pharmaceutical and non-pharmaceutical interventions on COVID-19 in Tunisia.</ArticleTitle><Pagination><StartPage>2803</StartPage><MedlinePgn>2803</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2803</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-19236-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In COVID-19 management, a variety of pharmaceutical interventions (PI) and non- pharmaceutical interventions (NPI) were adopted to limit the spread of the disease and its associated deaths. We aimed to evaluate the impact of PI and NPI on risks of COVID-19 transmission and deaths.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We collected aggregate data from March 2nd, 2020, to December 1, 2022 from the Tunisian Ministry of Health's website and OurWorldInData.org site. NPI Periods (NPIP: March 2020 to March 2021) and PI Periods (PIP) were distributed to NPIP1, 2, 3 and 4 and to PIP1, 2, 3 and 4, respectively. We calculated the Relative Risks (RR) and 95% Confidence Intervals (CI) by comparing the subsequent period with previous one.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The risk of SARS-CoV-2 transmission increased progressively from the zero cases period (NPIP2) to the mitigate strategy period (NPIP3) (RR = 14.0; 95% CI: 12.4-15.8) and to the stop-and-go epidemic control period (NPIP4) (RR = 23.1 (95% CI: 22.4-23.9). It was stabilized in the targeted vaccination period (PIP1) (RR = 1.08, 95% CI: 1.07-1.08) and reduced during the mass vaccination period (PIP2) (RR: 0.50, 95% CI: 0.50-0.51). SARS-CoV-2 transmission, increased during PIP3 concomitant with the Omicron wave (RR = 2.65, 95% CI: 2.64-2.67). It remained at a low level in PIP4 (RR = 0.18; 95% CI: 0.18-0.18). Compared to NPIP2, NPIP3 and NPIP4 were associated with a higher risk of COVID-19 mortality (RR = 3.337; 95% CI: 1.797-6.195) and (RR = 72.63 (95% CI: 54.01-97.68), respectively. Since the start of the immunization program, the risk of COVID-19 death has consistently decreased. In comparison to each previous period, the risk transitioned in PIP1 to RR = 0.91; 95% CI: 0.88-0.93, then to RR = 0.85; 95% CI: 0.83-0.88 in PIP2, to RR = 0.47; 95% CI: 0.45-0.50 in PIP3, and to RR = 0.19; 95% CI: 0.18-0.24 during PIP4.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In terms of lowering the risk of transmission and mortality, the NP strategy at the beginning of the epidemic outperformed the IP strategy during the outbreak.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abroug</LastName><ForeName>Hela</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennasrallah</LastName><ForeName>Cyrine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia. cyrine.bennasrallah@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia. cyrine.bennasrallah@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia. cyrine.bennasrallah@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Fredj</LastName><ForeName>Manel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacem</LastName><ForeName>Meriem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Belgacem</LastName><ForeName>Manel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhouib</LastName><ForeName>Wafa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gara</LastName><ForeName>Amel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maatouk</LastName><ForeName>Amani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zemni</LastName><ForeName>Imen</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Hassine</LastName><ForeName>Donia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallas</LastName><ForeName>Syrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Physiology Department, Faculty of Medecine of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouanene</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sriha Belguith</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preventive Medicine, University Hospital Fattouma Bourguiba of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Faculty of Medicine, University of Monastir, Monastir, 5000, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research LaboratoryTechnology and Medical Imaging- LTIM - LR12ES06, University of Monastir, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014416" MajorTopicYN="N" Type="Geographic">Tunisia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Health impact assessment</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Quarantine</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396980</ArticleId><ArticleId IdType="pmc">PMC11472591</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-19236-9</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-19236-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA. 2020;323(8):707–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31971553</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease (COVID-19) – World Health Organization [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Cited 2023 Sep 26.</Citation></Reference><Reference><Citation>Patiño-Lugo DF, Vélez M, Velásquez Salazar P, Vera-Giraldo CY, Vélez V, Marín IC, et al. Non-pharmaceutical interventions for containment, mitigation and suppression of COVID-19 infection. Colomb Med (Cali). 2020;51(2):e4266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518730</ArticleId><ArticleId IdType="pubmed">33012884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature. 2020;584(7820):262–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32512578</ArticleId></ArticleIdList></Reference><Reference><Citation>Iezadi S, Gholipour K, Azami-Aghdash S, Ghiasi A, Rezapour A, Pourasghari H, et al. Effectiveness of non-pharmaceutical public health interventions against COVID-19: A systematic review and meta-analysis. PLoS ONE. 2021;16(11):e0260371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610259</ArticleId><ArticleId IdType="pubmed">34813628</ArticleId></ArticleIdList></Reference><Reference><Citation>Patiño-Lugo DF, Vélez M, Velásquez Salazar P, Vera-Giraldo CY, Vélez V, Marín IC, et al. Non-pharmaceutical interventions for containment, mitigation and suppression of COVID-19 infection. Colomb Med (Cali). 2020;51(2):e4266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518730</ArticleId><ArticleId IdType="pubmed">33012884</ArticleId></ArticleIdList></Reference><Reference><Citation>Batteux E, Mills F, Jones LF, Symons C, Weston D. The Effectiveness of Interventions for Increasing COVID-19 Vaccine Uptake: A Systematic Review. Vaccines (Basel). 2022;10(3):386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949230</ArticleId><ArticleId IdType="pubmed">35335020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Our World in Data [Internet]. 2020 Mar 5; Available from: https://ourworldindata.org/covid-vaccinations. Cited 2022 Sep 23.</Citation></Reference><Reference><Citation>Cascini F, Failla G, Gobbi C, Pallini E, Hui J, Luxi W, et al. A cross-country comparison of Covid-19 containment measures and their effects on the epidemic curves. BMC Public Health. 2022;22(1):1765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482299</ArticleId><ArticleId IdType="pubmed">36115936</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidi O, Malouche D, Saksena P, Arfaoui L, Talmoudi K, Hchaichi A, et al. Impact of contact tracing, respect of isolation, and lockdown in reducing the number of cases infected with COVID-19. Case study: Tunisia’s response from March 22 to May 4, 2020. Int J Infect Dis. 2021;113:26–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872851</ArticleId><ArticleId IdType="pubmed">33578008</ArticleId></ArticleIdList></Reference><Reference><Citation>Labidi MA. How the COVID-19 Pandemic Affected Developing Countries: the Tunisian Investigation. J Knowl Econ. 2023;14(1):20–34.</Citation></Reference><Reference><Citation>Ben Fredj S, Ghammem R, Zammit N, Maatouk A, Haddad N, Haddad N, et al. Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. BMC Infect Dis. 2022;22(1):894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706846</ArticleId><ArticleId IdType="pubmed">36443699</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistiques | INS [Internet]. Available from: http://www.ins.tn/statistiques/111. Cited 2022 Nov 10.</Citation></Reference><Reference><Citation>ONMNE Tunisie | Ministère de la santé [Internet]. Available from: https://www.onmne.tn/. Cited 2022 Nov 10.</Citation></Reference><Reference><Citation>Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">33686204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus Pandemic (COVID-19). Our World in Data [Internet]. 2020 Mar 5; Available from: https://ourworldindata.org/coronavirus. Cited 2023 Sep 26.</Citation></Reference><Reference><Citation>Mortality surveillance threshold [Internet]. UNHCR. 2024. Available from: https://emergency.unhcr.org/emergency-assistance/health-and-nutrition/mortality-surveillance-threshold. Cited 2024 Jan 22.</Citation></Reference><Reference><Citation>Irwig L, Irwig J, Trevena L, Sweet M. Relative risk, relative and absolute risk reduction, number needed to treat and confidence intervals. In: Smart Health Choices: Making Sense of Health Advice [Internet]. Hammersmith Press; 2008. Available from: https://www.ncbi.nlm.nih.gov/books/NBK63647/. Cited 2024 Jan 22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22013602</ArticleId></ArticleIdList></Reference><Reference><Citation>Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223792</ArticleId><ArticleId IdType="pubmed">32404476</ArticleId></ArticleIdList></Reference><Reference><Citation>Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ. 2021;17:e068302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9423125</ArticleId><ArticleId IdType="pubmed">34789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarra M, Kebir A, Talla C, Barry A, Faye J, Louati D, et al. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. BMJ Glob Health. 2022;7(2):e007236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882665</ArticleId><ArticleId IdType="pubmed">35193893</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder T, Külper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021;26(41):2100920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518304</ArticleId><ArticleId IdType="pubmed">34651577</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021. PLoS ONE. 2022;17(9):e0274008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469958</ArticleId><ArticleId IdType="pubmed">36099273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;20(374):n1943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377789</ArticleId><ArticleId IdType="pubmed">34417165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco ME, Soldato G, Acuti Martellucci C, Carota R, Di Luzio R, Caponetti A, et al. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. Vaccines (Basel). 2021;9(6):628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227269</ArticleId><ArticleId IdType="pubmed">34200538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Hu S, Lin Q, Ren T, Chen L. China’s ‘dynamic zero COVID-19 strategy’ will face greater challenges in the future. J Infect. 2022;85(1):e13–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015719</ArticleId><ArticleId IdType="pubmed">35447231</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhakrishnan N, Liu M, Idowu B, Bansari A, Rathi K, Magar S, et al. Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. BMC Infect Dis. 2023;23(1):747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10617227</ArticleId><ArticleId IdType="pubmed">37907849</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi M, Al-Najjar Y, Mhaimeed N, Salameh MA, Paul P, AlAnni J, et al. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review. J Cell Mol Med. 2023;27(11):1443–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243162</ArticleId><ArticleId IdType="pubmed">37203288</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>